About this trial
The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline indicators for patients with colorectal liver metastases (CRLM) after surgery. By combining micro-level radiomics signatures reflecting tumor micro-heterogeneity with macro-level clinical parameters (such as liver function and tumor biomarkers), the study aims to accurately evaluate individual post-operative prognostic risks. This quantitative tool will provide reliable decision support for clinicians to customize post-operative follow-up and personalized adjuvant treatment strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
The study population consists of adult patients diagnosed with colorectal liver metastases who underwent surgical resection across multiple participating clinical centers, featuring high-quality preoperative liver MRI scans and complete clinical follow-up histories.
Trial design
Cohort
Retrospective
Treatments tested in this trial
Multimodal Predictive Evaluation
Procedure/SurgeryObservational and non-invasive assessment based on preoperative MRI-derived 3D modeling and three-dimensional lesion reconstruction, combined with clinical parameters, to build a survival prediction model. No experimental intervention is assigned.
Treatment groups
Trial outcomes
Primary outcomes
Recurrence-Free Survival (RFS)
Recurrence-free survival (RFS) is defined as the time from the date of surgical resection to the date of first tumor recurrence (local, regional, or distant) or death from any cause, whichever occurs first.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Anhui Provincial Hospital
Lead sponsor
Anhui Provincial Cancer Hospital
Collaborator